Structure Therapeutics (NASDAQ:GPCR) Issues Earnings Results

Posted by on Aug 8th, 2026

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10), FiscalAI reports.

Structure Therapeutics Trading Up 1.0%

NASDAQ GPCR traded up $0.52 on Friday, hitting $53.14. 329,459 shares of the company were exchanged, compared to its average volume of 558,888. The company has a market cap of $3.78 billion, a PE ratio of -53.14 and a beta of -1.43. The stock has a fifty day moving average of $47.63 and a 200-day moving average of $54.19. Structure Therapeutics has a 12 month low of $15.86 and a 12 month high of $94.90.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP grew its stake in shares of Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after buying an additional 1,432,797 shares during the period. Janus Henderson Group PLC increased its position in Structure Therapeutics by 14.4% in the 4th quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock valued at $354,006,000 after buying an additional 641,322 shares in the last quarter. Morgan Stanley raised its stake in Structure Therapeutics by 261.4% during the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after buying an additional 1,510,093 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Structure Therapeutics by 477.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after buying an additional 1,381,745 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in Structure Therapeutics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock worth $32,939,000 after acquiring an additional 106,389 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GPCR shares. HC Wainwright reduced their price objective on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a report on Friday. Citizens Jmp cut their price target on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Get Our Latest Report on Structure Therapeutics

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

Featured Stories

Earnings History for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.